All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Gilles Salles explains why you should join the virtual Lymphoma Hub Satellite Symposium
Bookmark this article
The Lymphoma Hub will hold a virtual satellite symposium at the European Society of Hematology (ESH) 2nd How to Diagnose and Treat: Lymphoma conference, on November 8, 2020, at 3:50 P.M. (CET). The Lymphoma Hub Chair, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, explains why you should join the virtual Lymphoma Hub Satellite Symposium.
Gilles Salles explains why you should join the virtual Lymphoma Hub Satellite Symposium
While frontline treatment approaches in non-Hodgkin lymphomas and CLL have made tremendous progress, the treatment of patients with relapsed/refractory disease can be a challenge. During the Lymphoma Hub satellite symposium, five international experts, Gilles Salles, Marie-José Kersten, Kieron Dunleavy, Francesc Bosch, and Astrid Pavlovsky will provide an overview of the latest advances in the field, special treatment challenges, and regional differences in approaching treatment decisions for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic lymphoma (CLL).
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox